FDA staff who participated in the review of AstraZeneca’s EGFR tyrosine kinase inhibitor gefitinib; a feature of the Pink Sheet’s Drug Review Profile series.
You may also be interested in...
Iressa FDA Reviewers
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Seattle Genetics holds the award for fastest supplemental approval (11 days) and fastest new molecular entity approval (119 days) under the US FDA's RTOR program, according to the Pink Sheet's Performance Tracker.